Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study

EuroQol - a new facility for the measurement of health-related quality of life

Health Policy · 1990 · 15.5K citations

Quality Of Life, Life Assessment, Health Policy +7

Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use

A.Y. Finlay, Ghazala Khan · Clinical and Experimental Dermatology · 1994 · 5.4K citations

Quality Of Life, Life Assessment, Allergy +12

The Validity and Reproducibility of a Work Productivity and Activity Impairment Instrument

Margaret C. Reilly, Arthur S. Zbrozek, Ellen Dukes · PharmacoEconomics · 1993 · 2.9K citations

Productivity, Quality Of Life, Workforce Productivity +13

Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

Richard G. Langley, Boni E. Elewski, Mark Lebwohl et al. · New England Journal of Medicine · 2014 · 1.9K citations · Full text

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

Craig L. Leonardi, Alexa B. Kimball, Kim Papp et al. · The Lancet · 2008 · 1.9K citations

76-Week Results, Immunology, Clinical Trials +7